Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
What is City Talk? City Talk allows marketers to connect directly with our audience by publishing content on citypm.eu
Friday 07 October 2022 10:34 am  |  Updated:  Tuesday 11 October 2022 3:08 pm

Advances in eye health

By: May Griffith

Add as a preferred source on Google
Dissecting slaughterhouse pig eyes that we use for testing biomaterials, e.g. suturing practice.

May Griffith, PhD, Marie-Claude Robert, MD, Samir Jabbour, MD, and Isabelle Brunette, MD Department of Ophthalmology, Université de Montréal

The first-in-human attempt to regenerate the human cornea was a team effort led by May Griffith, who is currently a Université de Montréal (UdeM) professor of ophthalmology. Together with Isabelle Brunette and the Swedish clinical trial team led by Per Fagerholm, they reported the successful regeneration of the human cornea in a clinical trial of 10 Swedish patients.

A follow-up study was completed on six patients at high risk of rejecting conventional human donor cornea transplantation in collaboration with corneal surgeons at the LV Prasad Eye Institute in India and the Filatov Institute of Eye Diseases and Tissue Therapy in Ukraine. The cell-free implants were able to stimulate the patient’s own stem cells to regrow or regenerate new corneal tissue and nerves.

Patients with ulceration and scarring after severe infection showed the best outcomes after surgery with cell-free implants that stimulated the patients’ corneas to regrow new tissue in place of the removed
pathologic tissue.

Bursting pressure testing to ensure biomaterials will seal defects.

Vaccines have always been highly successful at reaching the masses. Together with Moorfields
Eye Hospital’s cornea specialist, Bruce Allan, and the UdeM team have been focusing on delivering an
injectable solution to seal perforations and act as an alternative to partial thickness transplantation. Proof of concept in animal studies shows promising results.

The development of the LiQD Cornea was a response to a challenge from Tej Kohli to Griffith and Allan on how they can expect to reach millions as solid implants, like donor corneas, will require expensive OR teams and time. While stem cells will be needed where these are deficient, the Montreal team and collaborators worldwide continue to work on therapies that include both biomaterials and stem cells.

The Tej Kohli & Ruit Foundation is a restricted fund operating under the auspices of Prism The Gift Fund, registered UK charity number 1099682.

Read more

Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Life&Style

Categories

  • Charity
  • Tech

Related Topics

  • Charity

Trending Articles

  • Revealed: Secret Treasury plan to tax State Pension before it is paid out

  • Two solicitors linked to Post Office scandal charged with misconduct

  • Burnham’s new chief of staff ran City firm advising Thames Water and rival Heathrow bidder

  • Barclays and Lloyds join banking sector plan for digital ID

  • Reeves’ new tax charge on cash ISAs faces fierce industry backlash

More from City PM

  • Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer

    Business Wire
  • cTAP Announces Novel Prognostic Score Developed for Duchenne Muscular Dystrophy Patients Offers Improved Prediction of Loss of Ambulation

    Business Wire
  • Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

    Business Wire
  • Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

    Business Wire
  • IMU Biosciences announces oversubscribed financing round, bringing its Series A to over $53M as it accelerates its work to decode the immune system with unprecedented resolution and scale, to transform how we understand, diagnose and treat disease

    Business Wire
  • Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

    Business Wire
  • Reply and IEO Launch Collaboration to Co-Develop and Train Domain-Specific Large Language Models for Oncology

    Business Wire
  • morph Launches the World’s First Shapeshifting Soft Robotics Cells Platform to Bring Physical AI into Real-World Applications

    Business Wire

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM. All rights reserved.
About · Contact · Terms · Privacy